Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two Sarpogrelate HCl 300mg Formulations
NCT03573622Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- May 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sarpodipil in Peripheral Arterial Disease (PAD) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration and Area under the plasma concentration versus time curve. Started May 2018; status: completed.
02
Drugs
sarpodipil
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT03573622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573622.